Brief: Viracta Therapeutics Announces Interim Data From Phase 1B/2 Clinical Trial Of Nana-Val

Viracta Therapeutics

04/12/2023 13:52

Dec 4 (Reuters) - Viracta Therapeutics Inc  VIRX.O :
    * VIRACTA THERAPEUTICS ANNOUNCES INTERIM DATA FROM PHASE
1B/2
CLINICAL TRIAL OF NANA-VAL IN PATIENTS WITH EPSTEIN-BARR
VIRUS-POSITIVE SOLID TUMORS THAT SHOW CONFIRMED TUMOR RESPONSES
AT HIGHER DOSE LEVELS
    * VIRACTA THERAPEUTICS INC: ENROLLMENT IS UNDERWAY FOR SIXTH
DOSE
COHORT OF PHASE 1B DOSE ESCALATION PORTION OF STUDY
    * VIRACTA THERAPEUTICS INC: PLANS TO INITIATE A RECOMMENDED
PHASE
2 DOSE-OPTIMIZATION COHORT AS PART OF STUDY'S PHASE 2 EXPANSION
IN 2024

Source text for Eikon:  ID:nGNX39sdJl 
Further company coverage:  VIRX.O 

 ((reuters.briefs@thomsonreuters.com;))